Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H2 | P55055 | 2/20 | 0.54 |
| ▸ | P2RX7 | Q99572 | 7/20 | 0.44 |
| ▸ | HRH3 | Q9Y5N1 | 4/20 | 0.42 |
| ▸ | GPR119 | Q8TDV5 | 3/20 | 0.41 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.41 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.40 |
| ▸ | PDE7A | Q13946 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29507776 | 1.00 | NR1H2 (0.54) | NR1H2P2RX7HRH3GPR119ESR2 | |
| SCHEMBL4537183 | 0.89 | P2RX7 (0.55) | P2RX7SMN1; SMN2 | |
| SCHEMBL1662960 | 0.88 | P2RX7 (0.44) | NR1H2P2RX7HRH3GPR119ESR2 | |
| SCHEMBL1584703 | 0.86 | CPS1 (0.46) | NR1H2P2RX7HRH3GPR119 | |
| SCHEMBL28692485 | 0.85 | ALDH1A1 (0.54) | P2RX7 | |
| SCHEMBL30734152 | 0.84 | MEN1 (0.51) | NR1H2P2RX7SMN1; SMN2 | |
| SCHEMBL1583488 | 0.84 | MEN1 (0.51) | NR1H2P2RX7SMN1; SMN2 | |
| SCHEMBL29508938 | 0.84 | NR1H2 (0.53) | NR1H2GPR119SMN1; SMN2 | |
| SCHEMBL660403 | 0.84 | NR1H2 (0.53) | NR1H2GPR119SMN1; SMN2 | |
| SCHEMBL22650385 | 0.82 | NR1H2 (0.44) | NR1H2P2RX7ESR2PDE4BPDE7A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220273659-A1 | HETEROCYCLIC COMPOUNDS AS KINASE INHIBITORS | NUVATION BIO OPERATING COMPANY LLC | 2022-09-01 | — | — | US | disclosed |
| EP-3993802-A1 | HETEROCYCLIC COMPOUNDS AS KINASE INHIBITORS | Nuvation Bio Inc. (US) | 2022-05-11 | — | — | EP | disclosed |
| CN-114340634-A | Heterocyclic compounds as kinase inhibitors | 诺维逊生物股份有限公司 | 2022-04-12 | — | — | CN | disclosed |
| CN-113880816-A | Piperazine-containing aminopyrimidine derivative and application thereof | 杭州百诚医药科技股份有限公司 | 2022-01-04 | — | — | CN | disclosed |
| WO-2021003314-A1 | HETEROCYCLIC COMPOUNDS AS KINASE INHIBITORS | NUVATION BIO INC. (US) | 2021-01-07 | — | — | WO | disclosed |
| WO-2021003314-A1 | HETEROCYCLIC COMPOUNDS AS KINASE INHIBITORS | NUVATION BIO INC. (US) | 2021-01-07 | — | — | WO | disclosed |
| WO-2020224568-A1 | CDK INHIBITORS | QILU REGOR THERAPEUTICS INC. (CN) | 2020-11-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220273659-A1 | HETEROCYCLIC COMPOUNDS AS KINASE INHIBITORS | CDK4, CDK6, CDK8 | NR1H2 4055/4885P2RX7 4026/4885HRH3 1963/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.